Cantor Fitzgerald has revised its earnings projection for United Therapeutics, raising the biotechnology firm’s estimated 2025 earnings to $28.70 per share. The announcement points to growing confidence in the company’s potential for continued expansion.

Castle Biosciences (NASDAQ: CSTL) received a resounding vote of confidence this week when Canaccord Genuity Group reaffirmed its “buy” rating. The firm’s price objective of $37.00 points to a potential 61.29% upside for the company’s shares.